Drugs / Sulsintilimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06590844 | Dec 2023 → Mar 2026 | hepatocellular carcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulsintilimab | “Tybo Sulsintilimab ® 200mg IV” NCT06590844 ↗ |
| Known as | Tybo | “Tybo Sulsintilimab ® 200mg IV” NCT06590844 ↗ |
| Route | Intravenous | “Tybo Sulsintilimab ® 200mg IV” NCT06590844 ↗ |